Checkmate Pharmaceuticals, Inc. Stock price

CMPI

US1628181083

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2022-05-27 pm EDT			5-day change	1st Jan Change
10.5 ^USD	-.--%		+0.38%	+265.85%

2022	Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	MT
2022	Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	MT

Chart Checkmate Pharmaceuticals, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Checkmate Pharmaceuticals, Inc.

Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	2022	MT
Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	2022	MT
Checkmate Pharmaceuticals, Inc. Appoints Robert E. Landry as Chief Financial Officer	2022	CI
Checkmate Pharmaceuticals, Inc. Announces Board Changes	2022	CI
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from NASDAQ Composite Index	2022	CI
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index	2022	CI
Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.	2022	CI
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting	2022	CI
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	2022	CI
Kuros Biosciences' Q1 Medical Devices Sales Surge 102% Following US FDA Approval For MagnetOs	2022	MT
BTIG Downgrades Checkmate Pharmaceuticals to Neutral From Buy	2022	MT
Sector Update: Health Care Stocks Carried Higher in Rising Tuesday Markets	2022	MT
Sector Update: Health Care Stocks Carried Higher in Rising Tuesday Markets	2022	MT
Top Midday Gainers	2022	MT
Sector Update: Health Care	2022	MT

More news

Analyst Recommendations on Checkmate Pharmaceuticals, Inc.

BTIG Downgrades Checkmate Pharmaceuticals to Neutral From Buy	2022	MT
BTIG Adjusts Checkmate Pharmaceuticals' Price Target to $9 from $29, Keeps Buy Rating	2022	MT
CHECKMATE PHARMACEUTICALS : BofA Securities Upgrades Checkmate Pharmaceuticals to Buy From Neutral, Price Target at $7	2021	MT

More recommendations

Press releases Checkmate Pharmaceuticals, Inc.

Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment	2022	AQ
Checkmate Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K	2022	PU
CHECKMATE PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	2022	AQ
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	2022	GL
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	2022	AQ

More press releases

News in other languages on Checkmate Pharmaceuticals, Inc.

Bourse Zurich: rebond technique, le SMI finit au-dessus des 11'500 points	2022
Kuros reçoit un paiement d'étapes après la cession de Checkmate	2022
Kuros erhält durch Checkmate-Übernahme Meilensteinzahlung von 5 Mio USD	2022
Bourse Zurich: dans le vert, à la faveur d'un rebond technique	2022
Kuros Biosciences double ses revenus issus des produits en 2021	2022

More news

Managers and Directors - Checkmate Pharmaceuticals, Inc.

Managers	Title	Age	Since
Arthur M. Krieg CEO	Chief Executive Officer	65	2015
Robert Landry DFI	Director of Finance/CFO	59	2022
Chris French CTO	Chief Tech/Sci/R&D Officer	-	2016

Members of the board	Title	Age	Since
Arthur M. Krieg CEO	Chief Executive Officer	65	2015
Nouhad Husseini BRD	Director/Board Member	-	2022

More insiders

Checkmate Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. The Company's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The Company is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The Company is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The Company's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CHECKMATE PHARMACEUTICALS, INC.	+265.85%	231 M $
REGENERON PHARMACEUTICALS, INC.	+13.25%	87 558 M $
WUXI APPTEC CO., LTD.	-7.78%	32 140 M $
ARGENX SE	+23.14%	26 934 M $
BIONTECH SE	-34.58%	23 750 M $
GENMAB A/S	-25.30%	20 820 M $
BEIGENE, LTD.	-16.11%	18 870 M $
NEUROCRINE BIOSCIENCES, INC.	-1.80%	11 449 M $
LEGEND BIOTECH CORPORATION	+25.50%	11 389 M $
SAREPTA THERAPEUTICS, INC.	-31.91%	8 056 M $